7 Mar 2016 07:00
7 March 2016
ABCAM PLC
("Abcam" or "the Company")
Directorate Change
Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that after fifteen years at Abcam, Jim Warwick has today served notice of his intention to retire from Abcam and step down from the Board by the end of 2016. Jim remains committed to the Company and will continue to work with the executive team to lead existing activities and plan the transition of his role. Over his time with Abcam Jim has had a variety of roles and most recently as Chief Operating Officer (COO) he has led Innovation & Manufacturing, IT, Operations and Human Resources (HR) activity. Jim's role as COO will not be replaced. Instead the business will be restructured with IT, Operations and HR each joining the Chief Executive Officer's direct reports.
Alan Hirzel, CEO of Abcam, said:
"Jim has played a key role in Abcam's journey and has shaped a large part of our success. We will work with him on how we manage his portfolio of work and setting up the business with new key roles to support our next phase of growth and change. We have recently appointed Nick Skinner as our Global Human Resources Director, and he has already commenced a search for a Chief Information Officer and will shortly initiate the search for a Global Supply Chain Operations Leader. Jim will lead the rollout of our new technology platform and will be working with us until the end of 2016; a reflection of his commitment to the business."
Jim Warwick, COO, said:
"Over the last fifteen years it has been a privilege to be a part of the Abcam journey. Seeing the tremendous success and growth of the business into a global market leader is humbling. I remain committed to the business and excited about continuing to lead the rollout of our new technology platforms."
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Alan Hirzel, Chief Executive Officer Jeff Iliffe, Chief Financial Officer Julia Wilson - Investor Relations
|
|
J.P.Morgan Cazenove - Nominated Advisor & Corporate Broker | + 44 (0) 20 7742 4000 |
James Mitford / Alex Bruce |
|
|
|
FTI Consulting | + 44 (0) 20 3727 1000 |
Ben Atwell / Brett Pollard / Natalie Garland-Collins |
|
Notes for editors:
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.
By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Abcam's ten offices are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and www.abcamplc.com